Post-earnings recap
Reported
Thu, May 5, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CytomX Therapeutics reported a loss per share of $0.37, which was slightly below expectations. The stock reacted negatively, declining by 5.85%. The lack of revenue information and guidance may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | -5.11% |
| Revenue | — | N/A | — |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.